Corporate DealsLicense Agreement SignedOct 5, 2026 · 7:00am ET
ALECAlector, Inc.
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy
Agreement focuses on treatment for Parkinson’s Disease and other neurodegenerative diseases.
Corporate DealsLicense Agreement SignedOct 5, 2026 · 7:00am ET
ALECAlector, Inc.+76.1%
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy